ABSTRACT
Safety of administration of a vindesine (VDS)-anti-CEA conjugate and its ability to localise after radiolabelling were investigated in patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian). For imaging, patients received between 230 and 520 micrograms of 131I labelled antibody. In 5, localisation of conjugate was demonstrated, in another it was equivocal and in 2 patients, undetectable. For assessment of safety each patient also received a single dose of conjugate increasing from 1.2 to 42 mg antibody linked to 24 to 1800 micrograms VDS. The in vitro activity of the anti-CEA antibody and its ability to localise in vivo were preserved after conjugation. There was no obvious toxicity or hypersensitivity attributable to either the radiolocalisation or escalated doses of conjugate in any of the patients. The feasibility of the preparation and administration to patients of a vindesine-antibody conjugate has been demonstrated.
Subject(s)
Antibodies, Neoplasm/administration & dosage , Antineoplastic Agents/metabolism , Carcinoembryonic Antigen/immunology , Neoplasms/metabolism , Vinblastine/analogs & derivatives , Colonic Neoplasms/drug therapy , Drug Hypersensitivity/etiology , Female , Humans , Neoplasms/immunology , Ovarian Neoplasms/drug therapy , Rectal Neoplasms/drug therapy , Vinblastine/adverse effects , Vinblastine/metabolism , VindesineABSTRACT
Primary and secondary gastrointestinal tumors have been identified using sheep immunoglobulin G antibody to carcinoembryonic antigen radiolabeled with 131I. 99mTc-pertechnetate and 99mTc-human serum albumin were used to identify tissue spaces and blood pool and to facilitate external substraction imaging. In 13 patients with tumors, 4 of 5 primary sites and 8 of 11 secondary sites were successfully demonstrated. Two patients with benign disease had negative scans. Comparison with conventional methods of scanning showed good correlation.
Subject(s)
Antibodies, Neoplasm/administration & dosage , Carcinoembryonic Antigen/immunology , Gastrointestinal Neoplasms/diagnostic imaging , Radionuclide Imaging/methods , Carcinoembryonic Antigen/analysis , Gastrointestinal Neoplasms/immunology , Humans , Immunoglobulin G/administration & dosage , Iodine Radioisotopes , Technetium , Time FactorsABSTRACT
Sheep IgG antibody to carcinoembryonic antigen (CEA) was radiolabelled with 131I and used to identify human gastrointestinal tumours by external subtraction imaging. 99Tc-pertechnetate and 99Tc-human serum albumin were used to identify tissue spaces. In 13 patients with tumours four out of five primary sites and eight out of 11 secondary sites were successfully shown. Two patients with benign disease had negative scans. Comparison with conventional methods of scanning showed good correlation. The success of this pilot study should encourage the search for more tumour-specific antigens and further study of the implications for treatment.
